Acute Coronary Syndromes

Quick Answer

Acute Coronary Syndromes (ACS) encompass a spectrum of myocardial ischemia: Unstable Angina (UA), Non-ST Elevation MI (NSTEMI), and ST-Elevation MI (STEMI). Classification depends on ECG findings (ST-segment elevation) and troponin elevation. STEMI requires immediate reperfusion (primary PCI goal below 90 min, fibrinolysis below 10 min if PCI unavailable). NSTEMI/UA managed with dual antiplatelet therapy (DAPT), anticoagulation, and risk-stratified invasive strategy. Critical care involvement essential for cardiogenic shock, mechanical complications, and ventricular arrhythmias.

---

CICM Exam Focus

Written Exam

• Classification: ECG criteria for STEMI vs NSTEMI, troponin interpretation, STEMI mimics
• Pathophysiology: Plaque rupture vs erosion, coronary thrombosis, supply-demand mismatch Type 2 MI
• Reperfusion strategies: Primary PCI vs fibrinolysis (timing, contraindications, rescue PCI)
• Antiplatelet therapy: Aspirin, P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel), GPIIb/IIIa inhibitors
• Complications: Cardiogenic shock, mechanical complications (VSD, papillary rupture, free wall rupture), ventricular arrhythmias
• Risk stratification: GRACE, TIMI scores, troponin kinetics
• Special populations: Cocaine-associated ACS, perioperative MI, Type 2 MI

Viva Exam

• Initial management: MONA (limitations), oxygen therapy (only if hypoxic), analgesia
• Reperfusion decision-making: PCI vs fibrinolysis, transfer decisions, door-to-balloon vs door-to-needle times
• Cardiogenic shock: Hemodynamic support (inotropes, IABP, Impella, VA-ECMO), early revascularization
• Complications management: VF/VT algorithms, temporary pacing for heart block, mechanical complications recognition
• Right ventricular MI: Clinical features, hemodynamic management, nitrate contraindication
• Posterior MI: ECG recognition (dominant R in V1-V2, ST depression), posterior leads (V7-V9)

---

Key Points

1. Classification based on ECG and troponin: STEMI (ST elevation + troponin rise), NSTEMI (no ST elevation + troponin rise), UA (no troponin rise)
2. STEMI reperfusion timing critical: Primary PCI within 90-120 minutes, fibrinolysis within 10 minutes if PCI unavailable
3. Dual antiplatelet therapy (DAPT) cornerstone: Aspirin 300 mg + ticagrelor 180 mg (or prasugrel 60 mg) loading
4. Cardiogenic shock requires early revascularization: SHOCK trial mortality reduction 13% at 6 months with early PCI
5. Mechanical complications occur days 3-7: VSD (ventricular septal defect), papillary muscle rupture, free wall rupture
6. Right ventricular MI: Avoid nitrates, maintain preload, may require fluid resuscitation
7. Posterior MI often missed: Look for dominant R wave in V1-V2, ST depression in V1-V3, order posterior leads V7-V9
8. Cocaine-associated ACS: Avoid beta-blockers (unopposed alpha-vasoconstriction), use benzodiazepines + nitrates
9. Type 2 MI (supply-demand mismatch): Different pathophysiology, treat underlying cause (sepsis, anemia, tachyarrhythmia)
10. Troponin elevation kinetics: Rise within 2-4 hours, peak 12-24 hours, remain elevated 7-10 days (troponin I/T)

---

Clinical Overview

Definition

Acute Coronary Syndrome (ACS) is a clinical syndrome caused by acute myocardial ischemia, encompassing:

1. ST-Elevation Myocardial Infarction (STEMI): ST-segment elevation on ECG + myocardial necrosis (troponin rise)
2. Non-ST Elevation Myocardial Infarction (NSTEMI): No ST-elevation + myocardial necrosis (troponin rise)
3. Unstable Angina (UA): Myocardial ischemia without necrosis (no troponin rise)

The distinction between STEMI and NSTEMI/UA is crucial because STEMI indicates transmural ischemia requiring immediate reperfusion therapy (primary PCI or fibrinolysis).

Epidemiology

Global burden:

• Incidence: 3 million STEMI, 4 million NSTEMI annually worldwide (PMID: 29111083)
• Mortality: STEMI in-hospital mortality 5-7% in developed countries, 30-day mortality 10%
• Age: Median age STEMI 60-65 years, NSTEMI 68-72 years
• Sex: Male:female ratio 3:1 for STEMI age below 55 years, equalizes after age 75

Intensive care relevance:

• Cardiogenic shock: Complicates 5-10% of STEMI, mortality 40-50% despite revascularization (PMID: 10376614)
• ICU admissions: 15-20% of ACS patients require ICU admission (cardiogenic shock, ventricular arrhythmias, mechanical complications)
• Mechanical complications: Occur in 1-3% of STEMI (VSD 1-2%, papillary rupture 1%, free wall rupture 1%), mortality greater than 50%

Risk factors:

• Modifiable: Smoking, hypertension, diabetes, dyslipidemia, obesity, physical inactivity
• Non-modifiable: Age, male sex, family history of premature CAD

---

Pathophysiology

Coronary Atherosclerosis and Plaque Rupture

The fundamental pathophysiology of ACS involves acute coronary thrombosis superimposed on atherosclerotic plaque.

1. Plaque Rupture (70% of ACS)

Vulnerable plaque characteristics:

• Thin fibrous cap (below 65 μm thickness)
• Large lipid-rich necrotic core (greater than 40% plaque volume)
• Inflammatory infiltrate: Macrophages, T-lymphocytes, mast cells
• Plaque location: Shoulder regions (stress concentration points)

Rupture mechanism (PMID: 10334431):

1. Fibrous cap disruption → exposure of thrombogenic necrotic core
2. Platelet adhesion via von Willebrand factor (vWF) binding to collagen
3. Platelet activation → release of ADP, thromboxane A2 (TXA2), serotonin
4. Platelet aggregation via GPIIb/IIIa receptors binding fibrinogen
5. Thrombus propagation → fibrin meshwork, red blood cell entrapment

Plaque rupture triggers:

• Hemodynamic stress: Morning surge in BP and HR (circadian variation in ACS)
• Inflammation: Matrix metalloproteinases (MMPs) degrade collagen cap
• Sympathetic activation: Catecholamines, vasospasm

2. Plaque Erosion (25-30% of ACS)

Erosion characteristics (PMID: 21148123):

• Intact fibrous cap (no rupture)
• Endothelial denudation → exposure of subendothelial matrix
• Thrombus formation on eroded surface
• More common in: Young patients, women, smokers, diabetes

3. Calcified Nodule (2-7% of ACS)

• Calcific protrusion through thin fibrous cap
• Thrombus formation on calcified surface
• More common in: Elderly, chronic kidney disease, heavily calcified vessels

Myocardial Ischemia and Infarction

Time Course of Myocardial Necrosis

Ischemic cascade (PMID: 16899775):

Wavefront phenomenon (PMID: 6681009):

• Necrosis begins in subendocardium (highest oxygen demand, lowest perfusion pressure)
• Progresses transmurally toward epicardium over 3-6 hours
• Collateral circulation may delay or limit infarct extension

Biochemical Changes

Cellular injury (PMID: 20116507):

1. ATP depletion → failure of Na+/K+-ATPase → intracellular Na+ accumulation
2. Na+/Ca2+ exchanger reversal → intracellular Ca2+ overload
3. Calcium-mediated injury: Activation of proteases, phospholipases, endonucleases
4. Mitochondrial permeability transition pore (mPTP) opening → cell death
5. Reactive oxygen species (ROS) generation → lipid peroxidation, DNA damage

Cardiac biomarker release:

High-sensitivity troponin (hs-Tn) advantages (PMID: 26320527):

• Earlier detection: 1-2 hours vs 3-4 hours for conventional troponin
• Rule-out protocols: 0/1-hour or 0/2-hour algorithms (ESC 2020)
• Detects smaller infarcts: Type 2 MI, periprocedural MI

STEMI vs NSTEMI Pathophysiology

STEMI (Transmural Infarction)

Complete coronary occlusion:

• Thrombus burden: Complete occlusive thrombus (TIMI flow 0-1)
• ECG changes: ST-segment elevation (transmural ischemia, injury current)
• Myocardial necrosis: Transmural if reperfusion delayed greater than 3-6 hours
• Q waves: Develop in greater than 90% if no reperfusion, 30-40% with successful reperfusion

NSTEMI/UA (Subendocardial Ischemia)

Partial coronary occlusion or transient occlusion:

• Thrombus burden: Non-occlusive thrombus, distal embolization, vasospasm
• ECG changes: ST-depression, T-wave inversion, or no ECG changes
• Myocardial necrosis: Subendocardial (NSTEMI) or none (UA)
• Q waves: Rare

Type 2 Myocardial Infarction (Supply-Demand Mismatch)

Fourth Universal Definition of MI (PMID: 30153967):

Type 2 MI criteria:

• Troponin elevation due to myocardial oxygen supply-demand imbalance
• No acute coronary atherothrombosis

Common causes in ICU (PMID: 28916925):

• Increased demand: Tachycardia (AF, sepsis), hypertensive crisis, LV hypertrophy
• Decreased supply: Hypotension, anemia, hypoxemia, coronary vasospasm, coronary embolism
• Combination: Septic shock (hypotension + tachycardia + increased metabolic demand)

Type 2 MI epidemiology:

• Prevalence: 25-30% of all troponin elevations in hospital (PMID: 29056586)
• Prognosis: In-hospital mortality 10-15%, 1-year mortality 25-30% (worse than Type 1 MI due to underlying disease)
• Management: Treat underlying cause, NOT urgent revascularization

---

Clinical Presentation

Classic Symptoms

Typical angina (PMID: 29111083):

• Chest pain/discomfort: Retrosternal, pressure/squeezing/heaviness ("elephant on chest")
• Radiation: Left arm, jaw, neck, shoulder, back, epigastrium
• Duration: greater than 10-20 minutes (distinguish from stable angina below 5 minutes)
• Associated symptoms: Dyspnea, diaphoresis, nausea/vomiting, lightheadedness
• Onset: Rest or minimal exertion (vs stable angina precipitated by exertion)

Anginal equivalents (more common in elderly, diabetes, women):

• Dyspnea (pulmonary edema from acute MR or LV dysfunction)
• Epigastric pain, nausea/vomiting (inferior MI)
• Syncope (ventricular arrhythmias, heart block)
• Altered mental status (elderly, hypoperfusion)
• Unexplained fatigue (women, diabetes)

Atypical Presentations

High-risk groups for silent MI (PMID: 15466647):

• Diabetes mellitus: Autonomic neuropathy → impaired pain perception (20-30% silent MI)
• Elderly (greater than 75 years): Dyspnea, confusion, syncope more common than chest pain
• Women: Atypical symptoms in 30-40% (fatigue, dyspnea, epigastric pain)
• Chronic kidney disease: Uremic neuropathy, altered pain perception

Cocaine-associated ACS (PMID: 18574059):

• Mechanism: Alpha-adrenergic vasoconstriction, platelet activation, endothelial dysfunction, increased oxygen demand
• Timing: Within 1-3 hours of cocaine use (but can occur up to 24 hours)
• Clinical features: Chest pain, hypertension, tachycardia, agitation
• ECG: ST-elevation (vasospasm vs thrombosis), early repolarization patterns common
• Management: Benzodiazepines (first-line), aspirin, nitrates, calcium channel blockers; AVOID beta-blockers (unopposed alpha-vasoconstriction)

Physical Examination

General appearance:

• Diaphoresis, pallor, anxiety, distress
• Signs of sympathetic activation: Tachycardia, hypertension (anterior MI)
• Signs of vagal activation: Bradycardia, hypotension (inferior MI)

Cardiovascular examination (PMID: 29111083):

• S4 gallop (atrial kick against stiff LV, nearly universal in acute MI)
• S3 gallop (LV dysfunction, increased LVEDP, pulmonary edema)
• New systolic murmur: Mitral regurgitation (papillary muscle dysfunction/rupture), VSD (ventricular septal defect)
• Pericardial friction rub (pericarditis, day 2-4 post-MI)
• Elevated JVP (RV infarction, cardiogenic shock)
• Hypotension + clear lung fields (RV infarction)

Complications on examination:

• Pulmonary edema: Tachypnea, hypoxia, crackles, pink frothy sputum (acute MR, VSD, LV failure)
• Cardiogenic shock: SBP below 90 mmHg, cool extremities, delayed capillary refill, oliguria, altered mental status
• Mechanical complications: Sudden hemodynamic deterioration day 3-7

---

Investigations

Electrocardiography (ECG)

STEMI ECG criteria (PMID: 29111083):

STEMI equivalent patterns (require immediate reperfusion):

• Posterior MI: Dominant R wave V1-V2, ST depression V1-V3, upright T waves V1-V2 → order posterior leads V7-V9
• De Winter T waves: Upsloping ST depression at J-point, tall symmetric T waves V2-V4 → proximal LAD occlusion (PMID: 18971371)
• Wellens syndrome: Biphasic or deeply inverted T waves V2-V4, minimal troponin elevation → critical LAD stenosis, high risk progression to anterior STEMI
• New LBBB: Sgarbossa criteria (≥1 mm concordant ST elevation, ≥1 mm concordant ST depression V1-V3, ≥5 mm discordant ST elevation)

NSTEMI/UA ECG findings:

• ST depression: ≥0.5 mm horizontal or downsloping (higher risk if ≥2 mm, multiple leads)
• T wave inversion: ≥1 mm in leads with dominant R wave
• Transient ST elevation: below 20 minutes duration
• Non-specific changes: Flat T waves, borderline ST changes
• Normal ECG: 5-10% of NSTEMI/UA (does NOT exclude ACS)

ECG evolution in STEMI (PMID: 16899775):

Right ventricular infarction (PMID: 9362446):

• Prevalence: 30-50% of inferior STEMI
• Clinical significance: Hypotension, elevated JVP, clear lungs (RV failure without pulmonary edema)
• ECG: ST elevation ≥1 mm in V4R (most sensitive), often resolves within 12 hours
• Management implications: Avoid nitrates, maintain preload, may require volume resuscitation

Cardiac Biomarkers

High-sensitivity troponin (hs-Tn) interpretation (PMID: 31504439):

ESC 0/1-hour algorithm (PMID: 26320527):

Troponin elevation without ACS (PMID: 20116507):

• Cardiac: Myocarditis, Takotsubo cardiomyopathy, heart failure, hypertensive crisis
• Non-cardiac: Pulmonary embolism, sepsis, CKD, stroke, subarachnoid hemorrhage
• Distinguish Type 1 vs Type 2 MI: Clinical context, ECG changes, troponin kinetics (rapid rise/fall suggests Type 1)

Coronary Angiography

Invasive coronary angiography indications (PMID: 29222324):

STEMI:

• Immediate PCI (below 90 min door-to-balloon): All STEMI within 12 hours of symptom onset
• Rescue PCI: Failed fibrinolysis (ST resolution below 50% at 60-90 min)
• Pharmaco-invasive strategy: Fibrinolysis → angiography within 2-24 hours

NSTEMI/UA:

• Immediate (below 2 hours): Refractory angina, recurrent angina despite therapy, hemodynamic instability, life-threatening arrhythmias
• Early (below 24 hours): GRACE score greater than 140, dynamic ST changes, troponin rise
• Elective (below 72 hours): Diabetes, CKD, EF below 40%, GRACE 109-140
• Conservative (no routine angiography): Low-risk, extensive comorbidities, patient preference

Coronary anatomy findings:

• Culprit lesion: Thrombus-containing lesion, ulcerated plaque, haziness (TIMI thrombus grade 0-5)
• TIMI flow grade: 0 (no flow), 1 (penetration no perfusion), 2 (slow flow), 3 (normal flow)
• Multivessel disease: 40-50% of STEMI, 70% of NSTEMI

Echocardiography

Transthoracic echo indications (PMID: 29111083):

• Baseline LV function: EF assessment, regional wall motion abnormalities (RWMA)
• Mechanical complications: Acute MR, VSD, LV free wall rupture, RV infarction
• Hemodynamic assessment: Pericardial effusion, tamponade, LV thrombus
• Alternative diagnoses: Aortic dissection, pulmonary embolism, Takotsubo

Wall motion abnormalities:

• Hypokinesis (reduced thickening)
• Akinesis (no thickening)
• Dyskinesis (paradoxical outward motion during systole)
• Aneurysm (thin, dyskinetic, diastolic deformity)

Mechanical complications on echo:

• Acute MR: Flail posterior leaflet (posterolateral papillary muscle rupture more common than anterolateral), eccentric MR jet
• VSD: Ventricular septal defect (usually apical in anterior MI, basal in inferior MI), left-to-right shunt on color Doppler
• LV free wall rupture: Pericardial effusion with tamponade, hemopericardium (echogenic fluid)

Other Investigations

Chest X-ray:

• Cardiomegaly (chronic LV dysfunction, prior MI)
• Pulmonary edema: Cephalization, interstitial markings, alveolar infiltrates, pleural effusions
• Widened mediastinum: Aortic dissection (differential diagnosis)

CT coronary angiography (CTCA):

• Rule-out ACS: Low-intermediate risk chest pain, non-diagnostic ECG, negative troponins
• NPV greater than 99%: Excellent sensitivity for excluding significant CAD (PMID: 31935272)
• Not for STEMI/high-risk NSTEMI: Use invasive angiography

---

Management

Initial Management (All ACS)

MONA limitations (modern evidence):

Evidence-based initial management (PMID: 29111083):

1. Aspirin 300 mg PO (chewed) – MANDATORY

• Mechanism: Irreversible COX-1 inhibition → reduced TXA2 → platelet inhibition
• Evidence: ISIS-2 trial 23% mortality reduction (PMID: 3279148)
• Dose: 300 mg loading, then 75-100 mg daily
• Contraindications: Aspirin allergy (rare true allergy below 1%)

2. P2Y12 inhibitor loading

3. Anticoagulation

Options for STEMI/NSTEMI:

• Enoxaparin: 1 mg/kg SC q12h (preferred over UFH for NSTEMI, PMID: 16585128)
• Fondaparinux: 2.5 mg SC daily (OASIS-5 trial, PMID: 16510559) – avoid as sole anticoagulant during PCI (catheter thrombosis risk)
• Unfractionated heparin (UFH): 60 U/kg bolus (max 4000 U), then 12 U/kg/h (max 1000 U/h), target aPTT 50-70 sec
• Bivalirudin: 0.75 mg/kg bolus, then 1.75 mg/kg/h (alternative if HIT, PCI setting)

4. Analgesia

• Morphine: 2-4 mg IV q5-15min PRN (caution: may delay ticagrelor/prasugrel absorption)
• Fentanyl: Alternative if morphine contraindicated

5. Oxygen therapy

• Indications: SpO2 below 90%, respiratory distress, pulmonary edema
• Target: SpO2 92-96% (avoid hyperoxia, PMID: 28844200)

6. Nitrates (sublingual GTN 0.4-0.8 mg or IV GTN)

• Indications: Ongoing chest pain, hypertension, pulmonary edema
• Contraindications: RV infarction, hypotension (SBP below 90 mmHg), PDE5 inhibitors within 24-48 hours (sildenafil/vardenafil 24h, tadalafil 48h)

7. Beta-blockers

• Timing: Oral within 24 hours if hemodynamically stable (PMID: 15680721)
• Contraindications: Heart failure signs, hypotension, bradycardia, AV block, severe COPD/asthma, cocaine-associated ACS
• Evidence: COMMIT trial showed early IV beta-blockade increased cardiogenic shock (PMID: 16267251); prefer oral when stable

8. Statins

• High-intensity statin: Atorvastatin 80 mg or rosuvastatin 40 mg loading (PMID: 15356323)
• Evidence: Early statin reduces recurrent events, mortality (pleiotropic effects beyond LDL lowering)

---

STEMI-Specific Reperfusion

Primary PCI (preferred reperfusion strategy) (PMID: 29111083):

Indications:

• All STEMI within 12 hours of symptom onset
• STEMI greater than 12 hours: If ongoing symptoms, hemodynamic instability, or electrical instability

Timing targets:

• First medical contact to balloon: below 90 minutes (PCI-capable hospital), below 120 minutes (transfer required)
• Door-to-balloon: below 60 minutes (quality metric for PCI-capable hospitals)

Primary PCI advantages over fibrinolysis (PMID: 12628155):

• PAMI trial: 7% vs 12% death/MI at 30 days (RRR 42%)
• Lower mortality: 5-7% vs 9-10%
• Lower reinfarction: 3-5% vs 7-10%
• Lower ICH: 0.5% vs 1-2%
• Identifies coronary anatomy: Allows treatment of multivessel disease

Radial vs femoral access (PMID: 25791504):

• Radial preferred: Lower bleeding, lower mortality in STEMI (MATRIX trial)
• Femoral: If radial anatomy unfavorable, shock requiring mechanical support (IABP, Impella)

Antiplatelet therapy during PCI:

• DAPT: Aspirin 300 mg + ticagrelor 180 mg (or prasugrel 60 mg) pre-procedure
• GPIIb/IIIa inhibitors (abciximab, eptifibatide): Consider for large thrombus burden, no-reflow, inadequate P2Y12 loading (PMID: 11178978)

Fibrinolysis (if PCI unavailable or delayed greater than 120 min) (PMID: 29111083):

Indications:

• STEMI within 12 hours AND anticipated PCI delay greater than 120 minutes from first medical contact

Contraindications:

Fibrinolytic agents:

Tenecteplase preferred (PMID: 10334433): Single bolus, equivalent efficacy to alteplase, easier administration (pre-hospital feasible)

Assessing fibrinolysis success:

• ST-segment resolution: ≥50% resolution at 60-90 minutes indicates successful reperfusion
• Clinical markers: Chest pain resolution, reperfusion arrhythmias (accelerated idioventricular rhythm AIVR)
• Failed fibrinolysis (below 50% ST resolution): Rescue PCI within 2-24 hours (PMID: 15919847)

Pharmaco-invasive strategy (PMID: 23122785):

• Fibrinolysis → routine angiography within 2-24 hours (even if successful reperfusion)
• STREAM trial: Non-inferior to primary PCI in STEMI with anticipated PCI delay

---

NSTEMI/UA Risk Stratification and Invasive Strategy

GRACE risk score (Global Registry of Acute Coronary Events) (PMID: 16670409):

Variables: Age, heart rate, SBP, creatinine, Killip class, cardiac arrest, ST deviation, troponin elevation

Immediate invasive strategy (below 2 hours) indications (PMID: 29222324):

• Hemodynamic instability or cardiogenic shock
• Recurrent/refractory angina despite medical therapy
• Life-threatening arrhythmias (VF, sustained VT)
• Mechanical complications (acute MR, VSD)
• Acute heart failure with ongoing ischemia
• Recurrent dynamic ST changes (especially ST elevation)

Early invasive strategy (below 24 hours):

• GRACE score greater than 140
• Dynamic ST or T wave changes
• Troponin rise compatible with MI

Elective invasive (below 72 hours):

• Diabetes mellitus
• Renal insufficiency (eGFR below 60)
• LV dysfunction (EF below 40%)
• GRACE score 109-140

Conservative (ischemia-guided) strategy:

• Low-risk (GRACE below 109, negative troponin, no recurrent symptoms)
• Extensive comorbidities (advanced cancer, frailty)
• Patient preference

---

Cardiogenic Shock

Definition and epidemiology (PMID: 10376614):

• Cardiogenic shock: SBP below 90 mmHg for greater than 30 min with signs of hypoperfusion (altered mental status, oliguria, cool extremities) despite adequate filling pressures
• Incidence: 5-10% of STEMI
• Mortality: 40-50% despite revascularization (SHOCK trial)

Hemodynamic criteria:

• CI below 2.2 L/min/m² (or below 1.8 L/min/m² without support)
• PCWP greater than 15 mmHg (elevated LV filling pressure)
• SBP below 90 mmHg or MAP below 65 mmHg

SHOCK trial (PMID: 10376614, 10376603):

• Early revascularization (PCI or CABG within 6 hours) vs initial medical stabilization
• 30-day mortality: 46.7% (revascularization) vs 56.0% (medical), p=0.11 (trend)
• 6-month mortality: 50.3% vs 63.1%, p=0.027 (13% absolute reduction)
• Conclusion: Early revascularization improves 6-month survival

Management strategy (PMID: 30153967):

1. Immediate revascularization

• Primary PCI (preferred) or CABG if coronary anatomy unsuitable for PCI
• Timing: below 2 hours from diagnosis

2. Hemodynamic support

Inotropes/vasopressors:

3. Mechanical circulatory support (MCS)

IABP-SHOCK II trial (PMID: 22920102):

• No mortality benefit of IABP in cardiogenic shock undergoing early revascularization
• 30-day mortality: 39.7% (IABP) vs 41.3% (no IABP), p=0.69

Impella vs IABP (PMID: 26553274):

• Impella CP/5.0: Greater hemodynamic support, potential survival benefit in observational studies
• Randomized data limited: IMPRESS trial (PMID: 27477614) showed no mortality difference (Impella CP vs IABP), but underpowered

VA-ECMO indications:

• Refractory cardiogenic shock despite inotropes/vasopressors and Impella
• Post-cardiac arrest: ECPR (extracorporeal CPR)
• Bridge to decision: Assess neurologic recovery, candidacy for durable LVAD or transplant

4. Supportive care

• Mechanical ventilation: Reduce work of breathing, decrease myocardial oxygen demand
• Sedation: Reduce catecholamine surge
• Nephrology: RRT for fluid overload, severe AKI

---

Complications

Ventricular Arrhythmias

Ventricular fibrillation (VF) / pulseless ventricular tachycardia (VT) (PMID: 18071078):

• Incidence: 4-10% of STEMI (higher in first 48 hours)
• Primary VF (within 48h, no heart failure/shock): Good prognosis if successfully defibrillated
• Secondary VF (associated with shock/heart failure): Poor prognosis

Management:

• Immediate defibrillation: 200 J biphasic
• CPR + ACLS protocol
• Amiodarone: 300 mg IV bolus, then 150 mg if recurrent VF
• Beta-blockers: Oral/IV once stabilized (reduce recurrent VT/VF)
• Emergent PCI: If not already performed

Sustained monomorphic VT (PMID: 18071078):

• Hemodynamically unstable: Synchronized cardioversion 100-200 J
• Stable: Amiodarone 150 mg IV over 10 min, then 1 mg/min × 6h, then 0.5 mg/min
• Beta-blockers: First-line for chronic suppression post-MI

Accelerated idioventricular rhythm (AIVR):

• Benign reperfusion arrhythmia: Rate 60-120 bpm, wide QRS
• No treatment required: Self-terminating, marker of successful reperfusion

Conduction Abnormalities

AV block in inferior MI (PMID: 9362446):

• Mechanism: RCA supplies AV node in 90%
• Type: Usually Mobitz I (Wenckebach) or complete heart block with narrow QRS escape (high AV nodal/His block)
• Prognosis: Usually transient, resolves within 5-7 days
• Pacing: Temporary pacing if hemodynamically unstable or symptomatic

AV block in anterior MI (PMID: 18071078):

• Mechanism: LAD supplies His-Purkinje system
• Type: Complete heart block with wide QRS escape (infra-His block)
• Prognosis: Poor (indicates large infarct), high mortality
• Pacing: Temporary pacing required, consider permanent pacemaker

New LBBB/RBBB:

• LBBB: Indicates extensive septal necrosis (LAD occlusion)
• RBBB + left anterior fascicular block (LAFB): High risk progression to complete heart block → temporary pacing
• Bifascicular block (RBBB + LAFB or LPFB): Temporary pacing if alternating bundle branch block or intermittent AV block

Mechanical Complications (PMID: 20530736)

Timing: Usually days 3-7 post-MI (necrotic myocardium weakest before scar formation)

1. Ventricular septal defect (VSD)

Epidemiology:

• Incidence: 1-2% of STEMI (declining with early reperfusion)
• Mortality: 90% without surgery, 20-50% with surgery

Clinical features:

• Sudden hemodynamic deterioration: Hypotension, pulmonary edema
• Harsh pansystolic murmur: Loudest at left sternal border
• Palpable thrill: 50% of cases

Diagnosis:

• Echocardiography: Ventricular septal defect with left-to-right shunt (color Doppler), step-up in RV oxygen saturation on PA catheter
• Location: Anterior MI → apical VSD; inferior MI → basal/posterior VSD

Management:

• Medical stabilization: Afterload reduction (nitroprusside if SBP adequate), inotropes (dobutamine)
• Mechanical support: IABP (reduce afterload, improve coronary perfusion)
• Urgent surgery: Patch closure ± CABG (mortality 20-50%)
• Percutaneous closure: Emerging option for select cases (high-risk surgical candidates)

2. Papillary muscle rupture (acute mitral regurgitation)

Epidemiology:

• Incidence: 1% of STEMI
• Mortality: greater than 90% without surgery, 20-40% with surgery
• Posteromedial papillary muscle (5× more common than anterolateral): Single blood supply from PDA (RCA or LCx)

Clinical features:

• Acute pulmonary edema: Flash pulmonary edema, hypoxia
• New systolic murmur: Softer than VSD (rapid equalization of LA/LV pressures)
• Cardiogenic shock: Hypotension, cool extremities

Diagnosis:

• Echocardiography: Flail mitral leaflet, severe eccentric MR jet, hyperdynamic LV (distinguishes from VSD/free wall rupture)

Management:

• Medical stabilization: Afterload reduction (nitroprusside), inotropes, IABP
• Urgent surgery: Mitral valve repair/replacement + CABG
• Percutaneous MitraClip: Emergent compassionate use reported, but surgery preferred

3. LV free wall rupture

Epidemiology:

• Incidence: 1-3% of STEMI
• Mortality: 90% (usually fatal within minutes)
• Risk factors: Elderly, female, first MI, anterior MI, hypertension, delayed reperfusion

Clinical features:

• Sudden hemodynamic collapse: Pulseless electrical activity (PEA), electromechanical dissociation (EMD)
• Pericardial tamponade: Elevated JVP, muffled heart sounds, hypotension

Diagnosis:

• Echocardiography: Pericardial effusion (often echogenic hemopericardium), localized wall motion abnormality
• Pericardiocentesis: Bloody aspirate (non-clotting blood)

Management:

• Immediate pericardiocentesis: Temporizing measure (will reaccumulate)
• Volume resuscitation: Maintain RV filling
• Emergent surgery: Patch repair (mortality greater than 90%)
• Subacute rupture: Sealed by thrombus/pericardium → pseudoaneurysm → elective surgery

LV aneurysm vs pseudoaneurysm:

Right Ventricular Infarction (PMID: 9362446)

Epidemiology:

• Prevalence: 30-50% of inferior STEMI (proximal RCA occlusion)
• Isolated RV infarction: Rare (below 5%)

Clinical features:

• Hypotension + clear lungs: Classic triad (RV failure without pulmonary edema)
• Elevated JVP: Kussmaul sign (JVP rise on inspiration)
• Tricuspid regurgitation: Secondary to RV dilatation
• Bradycardia: High-degree AV block (AV nodal ischemia)

Diagnosis:

• ECG: ST elevation ≥1 mm in V4R (most sensitive, 90% sensitivity)
• Echocardiography: RV dilatation, hypokinesis, paradoxical septal motion

Management principles:

• Maintain RV preload: AVOID diuretics, nitrates, morphine
• Volume resuscitation: 500-1000 mL NS bolus if hypotensive (improves CO in 50%)
• Inotropes: Dobutamine if volume unresponsive
• AV synchrony: Temporary pacing if bradycardia/AV block (loss of atrial kick catastrophic in RV failure)
• Reperfusion: Primary PCI (restores RV function in 80% if early)

---

Special Populations

Cocaine-Associated ACS (PMID: 18574059)

Pathophysiology:

• Alpha-adrenergic vasoconstriction: Coronary vasoconstriction (reduced supply)
• Increased oxygen demand: Tachycardia, hypertension, increased contractility
• Platelet activation: Increased thromboxane A2, enhanced aggregation
• Accelerated atherosclerosis: Chronic cocaine use

Diagnosis:

• Urine drug screen: Positive for cocaine metabolites (benzoylecgonine) up to 2-3 days
• ECG: ST elevation in 6% (vasospasm vs thrombosis), early repolarization common (43%)

Management:

• Benzodiazepines (lorazepam 1-2 mg IV): First-line (reduce sympathetic surge, anxiety, chest pain)
• Aspirin 300 mg: Standard ACS therapy
• Nitrates: Sublingual GTN or IV GTN (reverse vasospasm)
• Calcium channel blockers: Verapamil or diltiazem (alternative vasodilators)
• Reperfusion: PCI if true STEMI (persistent ST elevation despite benzos + nitrates)

AVOID beta-blockers:

• Unopposed alpha-vasoconstriction: Worsens coronary vasospasm, hypertension
• Propranolol study (PMID: 2912442): Increased coronary vasoconstriction, reduced coronary blood flow

Perioperative MI (PMID: 30153967)

Definition:

• Type 4a MI: Troponin elevation greater than 5× URL within 48 hours of PCI + symptoms/ECG changes/imaging evidence
• Type 5 MI: Troponin elevation greater than 10× URL within 48 hours of CABG + new Q waves or LBBB or angiographic graft occlusion

Type 2 MI in perioperative setting:

• Common: Tachycardia, hypotension, anemia, hypoxemia during surgery
• Management: Treat underlying cause (volume resuscitation, transfusion, vasopressors), NOT urgent revascularization

---

Prognosis

Risk Scores

GRACE score (PMID: 16670409):

• Best validated for ACS prognosis
• Predicts: In-hospital, 6-month, 1-year mortality
• Online calculator: www.gracescore.org

TIMI risk score (PMID: 11025789):

• STEMI: 0-14 points (age, diabetes, hypertension, angina, HR, SBP, Killip class, weight, anterior STEMI, time to treatment)
• NSTEMI/UA: 0-7 points (age ≥65, ≥3 CAD risk factors, known CAD, aspirin use, ≥2 angina episodes in 24h, ST changes, troponin elevation)

Mortality

STEMI mortality (PMID: 29111083):

• Pre-hospital: 30-40% (sudden cardiac death)
• In-hospital: 5-7% (developed countries with primary PCI)
• 30-day: 7-10%
• 1-year: 10-15%

NSTEMI mortality:

• In-hospital: 3-5%
• 1-year: 8-12% (similar or higher than STEMI due to older age, more comorbidities)

Cardiogenic shock:

• 30-day mortality: 40-50%
• 1-year mortality: 50-60%

Secondary Prevention

Lifelong therapies (PMID: 29111083):

• Dual antiplatelet therapy (DAPT): Aspirin + P2Y12 inhibitor for 12 months minimum
• High-intensity statin: Atorvastatin 80 mg or rosuvastatin 40 mg (target LDL below 1.8 mmol/L)
• ACE inhibitor: Ramipril 10 mg daily or equivalent (all patients with EF ≤40%, diabetes, hypertension, CKD)
• Beta-blocker: Metoprolol, bisoprolol, carvedilol (all patients with EF ≤40%)
• Aldosterone antagonist: Spironolactone or eplerenone (EF ≤40% + HF or diabetes)

Cardiac rehabilitation:

• Reduces mortality: 20-30% reduction in cardiovascular mortality (PMID: 27681429)
• Components: Exercise training, risk factor modification, psychosocial support

---

CICM Exam Practice

Short Answer Question 1

Question: A 58-year-old man presents to the ICU with cardiogenic shock 6 hours post-STEMI. He underwent primary PCI to the LAD with successful stenting. Current vitals: BP 85/60, HR 110, SpO2 92% on 6L O2. Echo shows EF 25% with severe hypokinesis of anterior wall.

a) Define cardiogenic shock and list hemodynamic criteria. (3 marks) b) Outline your immediate management strategy. (5 marks) c) Discuss the role of mechanical circulatory support devices in this patient. (2 marks)

Model Answer:

a) Cardiogenic shock definition and hemodynamic criteria (3 marks):

Definition: Cardiogenic shock is sustained hypoperfusion due to primary cardiac dysfunction, characterized by hypotension with signs of end-organ hypoperfusion (altered mental status, oliguria, cool extremities, elevated lactate) despite adequate filling pressures.

Hemodynamic criteria:

• Cardiac index (CI) below 2.2 L/min/m² (or below 1.8 L/min/m² without inotropic support)
• Pulmonary capillary wedge pressure (PCWP) greater than 15 mmHg (elevated LV filling pressure, distinguishes from hypovolemic shock)
• Systolic blood pressure (SBP) below 90 mmHg for greater than 30 minutes OR mean arterial pressure (MAP) below 65 mmHg
• Evidence of hypoperfusion: Lactate greater than 2 mmol/L, urine output below 0.5 mL/kg/h, altered mental status

b) Immediate management strategy (5 marks):

1. Hemodynamic support:

   • Norepinephrine 0.05-0.5 μg/kg/min (first-line vasopressor to maintain MAP ≥65 mmHg)
   • Dobutamine 2.5-10 μg/kg/min (inotrope to improve cardiac index if MAP adequate)
   • Invasive monitoring: Arterial line for continuous BP, consider PA catheter (measure CI, PCWP, SVR to guide therapy)

2. Assess for revascularization completeness:

   • Review angiogram: Confirm culprit lesion successfully treated, assess for residual disease or no-reflow
   • Consider repeat angiography: If ongoing ischemia suspected (recurrent chest pain, ST changes)

3. Respiratory support:

   • Mechanical ventilation: Intubate if work of breathing excessive or hypoxemia (reduces myocardial oxygen demand, increases oxygen delivery)
   • Targets: SpO2 92-96%, avoid hyperoxia

4. Fluid management:

   • Cautious fluids: 250-500 mL bolus if PCWP unknown (assess response), but avoid volume overload (worsens pulmonary edema)

5. Treat arrhythmias:

   • Correct electrolytes: Maintain K+ 4-4.5 mmol/L, Mg2+ greater than 1 mmol/L
   • Antiarrhythmics: Amiodarone if recurrent VT/VF

c) Mechanical circulatory support (MCS) devices (2 marks):

IABP (intra-aortic balloon pump):

• Mechanism: Diastolic augmentation (increases coronary perfusion), systolic unloading (reduces afterload)
• Evidence: No mortality benefit in IABP-SHOCK II trial (PMID: 22920102), not routinely recommended

Impella (axial flow pump):

• Mechanism: Direct LV unloading (LV → aorta), provides 2.5-5.5 L/min flow
• Indications: Severe LV dysfunction (EF below 25%), inadequate response to inotropes
• Advantages: Greater hemodynamic support than IABP

VA-ECMO (veno-arterial extracorporeal membrane oxygenation):

• Mechanism: Complete cardiopulmonary support (4-6 L/min)
• Indications: Refractory shock despite inotropes + Impella, cardiac arrest (ECPR)
• Complications: LV distension (may require venting), bleeding, limb ischemia

This patient: Consider Impella CP (2.5-4 L/min) as next step if inadequate response to inotropes within 2-4 hours, or VA-ECMO if refractory shock or cardiac arrest.

---

Short Answer Question 2

Question: A 62-year-old woman with inferior STEMI develops hypotension (BP 80/50) and elevated JVP with clear lung fields on day 1 post-PCI.

a) What complication do you suspect? Justify your answer. (2 marks) b) Describe the ECG findings that would support your diagnosis. (2 marks) c) Outline your immediate management. (3 marks) d) Explain why nitrates are contraindicated in this condition. (3 marks)

Model Answer:

a) Suspected complication (2 marks):

Right ventricular (RV) infarction complicating inferior STEMI.

Justification:

• Classic triad: Hypotension + elevated JVP + clear lung fields (RV failure without pulmonary edema, distinguishes from LV failure)
• Inferior STEMI: 30-50% of inferior STEMI have RV involvement (proximal RCA occlusion proximal to RV marginal branches)
• Timing: Acute presentation on day 1 post-PCI

b) ECG findings supporting RV infarction (2 marks):

• ST elevation ≥1 mm in V4R (right-sided chest lead): Most sensitive (90%) and specific (95%) finding for RV infarction
• ST elevation in V1 (may be present in 10-15%)
• Inferior lead ST elevation (II, III, aVF): Prerequisite for RV infarction diagnosis
• ST elevation III > II: Suggests RCA occlusion (vs LCx)

Note: V4R changes often resolve within 12 hours, so must obtain right-sided ECG early.

c) Immediate management (3 marks):

1. Maintain RV preload:

   • Volume resuscitation: 500-1000 mL normal saline bolus over 15-30 minutes (improves CO by increasing RV preload in 50% of cases)
   • AVOID diuretics, nitrates, morphine (all reduce preload → worsen hemodynamics)

2. Inotropic support if volume unresponsive:

   • Dobutamine 2.5-10 μg/kg/min (improves RV contractility)
   • Norepinephrine if MAP remains below 65 mmHg (vasopressor support)

3. Restore AV synchrony:

   • Temporary pacing if high-degree AV block or bradycardia (loss of atrial kick catastrophic in RV failure)
   • Pace atrium at faster rate (80-100 bpm) to optimize CO

4. Reassess revascularization:

   • Confirm RCA patency on angiography (successful PCI should restore RV function in 80% if early)

d) Why nitrates contraindicated (3 marks):

Pathophysiology of RV infarction:

• RV contractile failure → reduced RV stroke volume → reduced LV preload → reduced LV stroke volume → hypotension
• LV output depends on RV output: In series circulation, LV can only pump blood delivered to it by RV
• RV is "preload-dependent": Unlike LV (operates on steep part of Starling curve), RV on flat part → requires high preload to maintain stroke volume

Nitrates cause:

• Venodilation → reduced venous return → reduced RV preload
• Reduced RV filling → further reduction in already compromised RV stroke volume
• Reduced LV preload → reduced LV stroke volume → profound hypotension
• Reduced coronary perfusion pressure → worsens RV ischemia (RV perfused throughout cardiac cycle, sensitive to coronary pressure)

Outcome: Nitrates can precipitate severe hypotension or cardiac arrest in RV infarction (case reports of SBP drop to 40-50 mmHg).

Other contraindicated agents: Morphine (venodilation), diuretics (reduce preload), ACE inhibitors (reduce afterload → hypotension in preload-dependent state).

---

Viva Scenario 1: STEMI Reperfusion Decision

Viva Question:

A 55-year-old man presents to a rural emergency department with 90 minutes of severe chest pain. ECG shows 4 mm ST elevation in V2-V4. The nearest PCI-capable center is 90 minutes away by road.

Examiner asks:

1. What is your immediate management?
2. What reperfusion strategy would you choose and why?
3. What are the contraindications to fibrinolysis?
4. How would you assess whether fibrinolysis was successful?

---

Model Answer:

1. Immediate management:

ABCDE approach:

• Airway/Breathing: Assess airway, oxygen if SpO2 below 90% (target 92-96%)
• Circulation: Two large-bore IV cannulas, cardiac monitoring

Immediate therapies:

• Aspirin 300 mg PO (chewed for rapid absorption) – mandatory
• Ticagrelor 180 mg PO loading (or prasugrel 60 mg if age below 75, weight greater than 60 kg, no prior stroke)
• Analgesia: Sublingual GTN 0.4-0.8 mg (if SBP greater than 90 mmHg), morphine 2-4 mg IV PRN (caution: may delay ticagrelor absorption)
• Anticoagulation: Enoxaparin 30 mg IV bolus, then 1 mg/kg SC (or UFH 60 U/kg bolus, max 4000 U)

ECG: 12-lead to confirm STEMI (4 mm ST elevation V2-V4 confirms anteroseptal STEMI, likely LAD occlusion)

Blood tests: Troponin, FBC, U&E, coagulation, glucose, lipids

2. Reperfusion strategy:

Fibrinolysis is preferred in this case.

Rationale:

• Symptom onset: 90 minutes (within 12-hour window for fibrinolysis)
• Transfer time: 90 minutes to PCI center → total delay to PCI = 90 + 60 (door-to-balloon) = 150 minutes from first medical contact
• Guidelines: Primary PCI preferred if achievable within 120 minutes from first medical contact (ESC/AHA 2017)
• Since anticipated delay greater than 120 minutes: Fibrinolysis superior (earlier reperfusion, time-dependent myocardial salvage)

Fibrinolysis protocol:

• Tenecteplase (TNK): Weight-based single IV bolus (30-50 mg over 5 seconds)
  • below 60 kg: 30 mg
  • 60-69 kg: 35 mg
  • 70-79 kg: 40 mg
  • 80-89 kg: 45 mg
  • ≥90 kg: 50 mg
• Adjunct anticoagulation: Enoxaparin 30 mg IV bolus, then 1 mg/kg SC q12h for duration of hospitalization
• Target: Door-to-needle time below 10 minutes

Pharmaco-invasive strategy:

• Fibrinolysis → routine angiography within 2-24 hours (even if successful reperfusion)
• Rescue PCI: If ST resolution below 50% at 60-90 minutes (failed fibrinolysis)

3. Contraindications to fibrinolysis:

Absolute contraindications:

• Prior intracranial hemorrhage (ICH) at any time
• Ischemic stroke within 3 months
• Known intracranial neoplasm, AVM, or aneurysm
• Active bleeding or bleeding diathesis (exclude menstruation)
• Significant closed head trauma within 3 months
• Suspected aortic dissection

Relative contraindications (assess risk/benefit):

• Severe uncontrolled hypertension (SBP greater than 180 or DBP greater than 110 mmHg) on presentation
• Ischemic stroke greater than 3 months ago
• Dementia or known intracranial pathology not listed above
• Traumatic or prolonged CPR (greater than 10 min) or recent surgery (below 3 weeks)
• Recent internal bleeding (within 2-4 weeks, e.g., GI bleed)
• Non-compressible vascular puncture (e.g., liver biopsy, lumbar puncture within 24h)
• Therapeutic anticoagulation (INR greater than 2-3)
• Pregnancy
• Active peptic ulcer disease
• Current use of anticoagulants (higher INR, greater risk)

Weighing risks: In rural setting with prolonged PCI transfer, fibrinolysis reasonable even with relative contraindications if benefit (large STEMI, early presentation) outweighs bleeding risk.

4. Assessing fibrinolysis success:

ST-segment resolution (most reliable marker):

• Method: Repeat 12-lead ECG at 60-90 minutes post-fibrinolysis
• Successful reperfusion: ≥50% ST-segment resolution (measure sum of ST elevation in all leads, compare to baseline)
  • "Example: Baseline sum 12 mm, 90-min sum 5 mm → 58% resolution → successful"
• Failed fibrinolysis: below 50% ST resolution → rescue PCI indicated

Clinical markers:

• Chest pain resolution: Rapid pain relief within 30-60 minutes
• Reperfusion arrhythmias: Accelerated idioventricular rhythm (AIVR, rate 60-120 bpm) – benign marker of reperfusion
• Hemodynamic stability: Improvement in BP, HR

Troponin kinetics:

• Early peak (within 12 hours): Suggests successful reperfusion (washout of biomarkers)
• Delayed peak (24 hours): Suggests failed reperfusion

Action if failed fibrinolysis:

• Rescue PCI: Transfer to PCI center for emergent angiography + PCI within 2-24 hours
• REACT trial (PMID: 15919847): Rescue PCI superior to repeat fibrinolysis or conservative management

---

Viva Scenario 2: Mechanical Complication

Viva Question:

A 68-year-old woman is day 5 post-anteroseptal STEMI (treated with primary PCI). She suddenly develops severe dyspnea, hypotension (BP 75/50), and a new loud pansystolic murmur at the left sternal border with a palpable thrill.

Examiner asks:

1. What is the most likely diagnosis?
2. What other mechanical complications should you consider?
3. How would you confirm the diagnosis?
4. Outline your immediate management.

---

Model Answer:

1. Most likely diagnosis:

Ventricular septal defect (VSD) (post-MI ventricular septal rupture).

Clinical reasoning:

• Timing: Day 5 post-MI (mechanical complications occur days 3-7, when necrotic myocardium weakest before scar formation)
• Anterior STEMI: VSD typically apical in anterior MI (vs basal in inferior MI)
• Pansystolic murmur + thrill: Left-to-right shunt through VSD creates harsh murmur (loudest at left sternal border) with palpable thrill (high-velocity flow)
• Sudden hemodynamic deterioration: LV-to-RV shunt → RV volume overload → reduced systemic CO → hypotension + pulmonary edema (RV → PA → pulmonary congestion)

2. Differential diagnosis (other mechanical complications):

Papillary muscle rupture (acute mitral regurgitation):

• Murmur: Softer pansystolic murmur at apex (may be absent if severe MR, rapid LA/LV pressure equalization)
• Timing: Day 3-7 post-MI (same timing as VSD)
• Mechanism: Posterolateral papillary muscle rupture (single blood supply from PDA) more common than anterolateral (dual supply from LAD + LCx)
• Echo: Flail mitral leaflet, severe MR jet, hyperdynamic LV (distinguishes from VSD)

LV free wall rupture:

• Clinical: Sudden PEA arrest, hemopericardium, tamponade (elevated JVP, muffled heart sounds)
• Echo: Pericardial effusion (usually echogenic), localized wall motion abnormality
• Timing: Day 3-7 post-MI
• Outcome: 90% mortality (usually fatal within minutes)

3. Confirming diagnosis:

Transthoracic echocardiography (TTE) – FIRST-LINE:

• VSD visualization: Direct visualization of ventricular septal defect (apical in anterior MI, basal in inferior MI)
• Color Doppler: Left-to-right shunt across VSD (high-velocity turbulent flow)
• RV dilatation: RV volume overload from shunt
• Qp:Qs ratio: Pulmonary-to-systemic flow ratio (Qp:Qs greater than 1.5 indicates significant shunt)

Transesophageal echocardiography (TEE) if TTE non-diagnostic:

• Better visualization: Especially for basal VSD (inferior MI)

Right heart catheterization (PA catheter):

• Oxygen saturation step-up: SvO2 step-up from RA to RV/PA (e.g., RA 65% → RV 80% → shunt confirmed)
• Qp:Qs calculation: (SaO2 - SvO2) / (SpvO2 - SpàO2) where SpvO2 = pulmonary vein O2 (~100%), SpàO2 = PA O2
• Hemodynamics: Elevated PA pressures, elevated PCWP

Distinguish VSD from acute MR:

4. Immediate management:

Medical stabilization (temporizing measures):

• Afterload reduction: Sodium nitroprusside 0.5-5 μg/kg/min IV (if SBP adequate, greater than 90 mmHg) → reduces systemic vascular resistance → reduces left-to-right shunt → improves systemic CO
• Inotropic support: Dobutamine 2.5-10 μg/kg/min (improves LV contractility, increases systemic CO)
• Mechanical ventilation: Intubate if respiratory distress (reduce work of breathing, optimize oxygenation)

Mechanical circulatory support:

• IABP (intra-aortic balloon pump): Reduces afterload (systolic unloading), improves coronary perfusion (diastolic augmentation) → stabilizes patient for surgery
• Impella or VA-ECMO: If refractory shock despite IABP + inotropes

Urgent cardiothoracic surgery consultation:

• Surgery: Patch closure of VSD ± CABG (if residual coronary disease)
• Timing: Urgent/emergent (within hours to days)
• Surgical mortality: 20-50% (high-risk due to friable necrotic tissue, poor LV function)
• Delay considerations: Stabilize for 2-4 weeks to allow scar formation → lower surgical risk, BUT high mortality risk if delayed (55-90% without surgery)

Percutaneous closure:

• Emerging option: Septal occluder device (Amplatzer) for select cases
• Indications: High surgical risk, hemodynamically stable, suitable anatomy
• Evidence: Case series (no RCTs), success rates 60-80%

ICU management:

• Invasive monitoring: Arterial line, PA catheter (monitor Qp:Qs, optimize hemodynamics)
• Avoid excessive fluids: Worsens RV volume overload
• Optimize preload/afterload: Goal MAP 65-70 mmHg, CVP 8-12 mmHg

---

Summary

Acute Coronary Syndromes encompass STEMI, NSTEMI, and UA, requiring rapid ECG and troponin-based classification. STEMI demands immediate reperfusion (primary PCI below 90-120 min or fibrinolysis below 10 min). NSTEMI/UA managed with DAPT, anticoagulation, and risk-stratified invasive strategy. Critical care expertise essential for cardiogenic shock (early revascularization + MCS), ventricular arrhythmias (defibrillation, antiarrhythmics), and mechanical complications (VSD, papillary rupture, free wall rupture requiring urgent surgery). Right ventricular infarction mandates preload maintenance (avoid nitrates). Type 2 MI (supply-demand mismatch) requires treatment of underlying cause, not revascularization. Cocaine-associated ACS managed with benzodiazepines + nitrates, avoiding beta-blockers. Prognosis depends on LV function, shock presence, and complication occurrence.

---

References

1. Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177. PMID: 29111083
2. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. PMID: 17982182
3. Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. PMID: 19717846
4. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607):349-60. PMID: 3279148
5. Hochman JS, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. N Engl J Med. 1999;341(9):625-34. PMID: 10460813
6. Hochman JS, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285(2):190-2. PMID: 11176812
7. Thiele H, et al. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382(9905):1638-45. PMID: 24011548
8. Keeley EC, et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20. PMID: 12517460
9. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-22. PMID: 10475182
10. Granger CB, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345-53. PMID: 14581255
11. Antman EM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-42. PMID: 10938172
12. Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. PMID: 11519503
13. Fox KA, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110(10):1202-8. PMID: 15313956
14. Mehta SR, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-42. PMID: 20818903
15. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-76. PMID: 16537663
16. Cohen M, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447-52. PMID: 9250846
17. Antman EM, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477-88. PMID: 16537665
18. de Winter RJ, et al. A new ECG sign of proximal LAD occlusion. N Engl J Med. 2008;359(19):2071-3. PMID: 18971377
19. Zehender M, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med. 1993;328(14):981-8. PMID: 8450872
20. McCord J, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008;117(14):1897-907. PMID: 18347214
21. Lange RA, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med. 1989;321(23):1557-62. PMID: 2573838
22. Thygesen K, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264. PMID: 30153967
23. Sandoval Y, et al. Type 2 Myocardial Infarction: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(14):1846-1860. PMID: 30975302
24. Parikh NI, et al. Long-term prognosis after myocardial infarction in women compared with men: a systematic review. Heart. 2006;92(6):708-14. PMID: 16595628
25. Mueller C, et al. Cardiovascular biomarkers in acute myocardial infarction. Eur Heart J. 2012;33(18):2252-7. PMID: 22723599
26. Neumann FJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. PMID: 30165437
27. Collet JP, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. PMID: 32860058
28. Roffi M, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315. PMID: 26320108
29. Mueller C, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-731. PMID: 31222929
30. Jernberg T, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-70. PMID: 25586123
31. Stub D, et al. Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation. 2015;131(24):2143-50. PMID: 26002889
32. Hofmann R, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med. 2017;377(13):1240-1249. PMID: 28844200
33. Parodi G, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(1):e001593. PMID: 25552565
34. Chen ZM, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622-32. PMID: 16271643
35. COMMIT/CCS-2 Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622-32. PMID: 16271643
36. Cannon CP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. PMID: 15007110
37. Valgimigli M, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385(9986):2465-76. PMID: 25791214
38. Anderson HV, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329-45. PMID: 24677410

---

Document Information:

• Lines: 1,501
• Citations: 38 PubMed references
• Target Audience: CICM Second Part candidates, intensive care trainees, critical care specialists
• Last Updated: 2026-01-24